

Real World Data Experience

RWD flagship programs and research project opportunities

Lise Bosquet, on belhalf of Anne-Laure Martin

Data and Partnership department

Summary









- 1. Who we are
- 2. Our RWD strategy
- 3. Our RWD flagship programs
- 4. Focus on ESME program









Who are we?

The Unicancer network











Local coverage of the national territory

- 18 French Comprehensive Cancer Centres (FCCCs): private, not-for-profit health centres, spread over 20 hospital sites in France
- 1 affiliated member to the GCS (health cooperation group groupement de coopération sanitaire)



We have highly qualified and specialised teams

 More than 21 000 professionals committed, on a daily basis, to a permanent quest for excellence in care, research and higher education



Unicancer

- The only French hospital federation dedicated to cancer (among the 4 national hospital federations in France)
- Defends the interests of the FCCCs and manages the National Collective Agreement
- o 1st academic sponsor of oncology clinical trials, at the European level



More than 530 000* patients treated each year

- More than 150 000 patients hospitalised per year
- Nearly 1 130 000 consultations



^{*} short-stay, hospitalization at home and outpatient procedures

^{**} inpatient and outpatient procedures

Our values









Humanism

≥ 21 000 women and men committed to humanistic medicine that respects each patient



Excellence

A permanent quest for excellence on a daily basis to be at the forefront of the fight against cancer



Solidarity

Health care centres dedicated to providing a public service, accessible to all patients without exceeding fees



Innovation

FCCCs are driven by a culture of research as a source of shared progress and by the ambition to improve treatment and care for all











Our RWD strategy



How we collect RWD?











Retrospective cohorts using hospital data

- No medical intervention
- Depend on hospital information system structuration and interoperability (patient records, imaging, molecular biology,...)
- Need an appropriate investment and a good ratio between the costs for high quality data collection or structuration and the reachable use cases...



Immediate usable information







- Prospective registration of the patients
- Possibility of prospective and systematic biobanking
- Possibility to add various PROMs / PREMs (not yet introduced in standard care)



Need sufficient follow-up before valorisation











Our RWD flagship programs



OncoDataHub










ODH, the oncology drug observatory, launch in September 2021

Target 2023: 80 French private and public hospital involved





Cancer toxicities










Canto, building a cancer survivorship research program on breast cancer

Next step (2022): extension to patient exposed to innovative treatments for localized cancer (breast and lung)



Inclusions started Feb 2012

LARGE DATABASE

LARGE BIOBANK

Blood serum plasma DNA microbiota



ESME, retrospective data










ESME, Epidemiological Strategy and Medical Economics

Longitudinal retrospective RWD on cancer management in oncology





Data administration using an Oracle Solution hosted by a « Certified Personal health data hosting » provider

Patient Database (200+)

Patient data collected based on electronic health records:

- Demographics
- Disease characteristics
- Treatments
- Clinical events

Treatment Database (10+)

On-site pharmacy records: Dates, cytotoxic drug, therapeutic protocol and other concomitant drugs

Hospital Database (20+)

- Hospitalizations (dates, diagnoses, GHS code)
- Medical procedures (including Radiotherapy): dates and code



Summary









The best way to answer questions

ESMÉ

- Epidemiology
- ✓ Therapeutic strategies efficacy evaluation
- ✓ Historical control arms
- ✓ Agencies pre-MA =>registration
- Agencies post MA => RWD complementary data
- ✓ Arificial intelligence



- Innovative treatment observatory and evaluation
- ✓ Therapeutic strategies evaluation
- ✓ Pan –tumor evaluations
- ✓ Institution and Hospital benchmark



- ✓ Patient burden measure
- Treatment toxicities and patient adherence
- Identification of patients at risk
- ✓ Social impact of disease and treatment
- ✓ Predictive algorithmes
- Personalisation of care
- ✓ Artificial intelligence

Digital tools for patients / physicians









Focus on ESME research program











From idea to data platform

Target indication





Available population





ESME project





ESME data platform



Partner support



- Health Authorities
- Academic/institutional
- Industrial

Dedicated cross-functional team:

- Central coordination
- Local coordinator(s)
- Expertise and Monitoring
- Data Protection Officer













Governance



Deontology Committee

International Advisory
Board



Working Groups

Local Coordinators











Centralization of existing data from patient medical files

An independent academic RWD platform supported by private funds

Independent

- Independence from stakeholders
- Raw data collected without medical interpretation
- Data collection processes and data acquisition handled by an academic organisation
- Centralized data analyses (specialized analysis centres)

Comprehensive

- Data collected from 20 comprehensive cancer centres and other health care institutions
- Target population at each centre (standard screening process)
- Robust dataset with sufficient variables to conduct quality analysis

Validated

- Piloted by a committee of academic experts
- Scientific expertise for data interpretation
- Standard quality assurance processes



Provide valid statistical outputs to answer public health questions












Three data platforms so far....



Adult women or men who began initial therapy* for metastatic breast cancer

Recruiting centres: 20 (FCCCs)

Patients: 28 000+ recruited



Adult women, who received therapy* or surgery or who were diagnosed with

ovarian cancer

Recruiting centres: 20 (FCCCs)

Patients: 12 000+ recruited



Adult women or men who began initial therapy* for advanced lung cancer, or who were diagnosed with metastatic lung cancer

Recruiting centres: 36 (FCCCs and other public hospitals)

Patients: 32 000+ recruited

*radiotherapy, chemotherapy, targeted therapy or hormone therapy in a participating center during the selection period











Objectives and opportunities

Describe patient care in routine medical practice and evaluate therapies efficiency in real life setting

- Describe cancer management in France and its evolution overtime
- Provide data on innovation drug use in medical institutions
 - Before marketing authorization and in real life setting
- Describe therapeutic trends (e.g. sequence of treatment strategies)
- Provide data to support requests from health authorities
 - Medical & economic assessment of therapeutic strategies
 - Description of patient management/settings (clinical features, therapeutic management, costs): linkage to data from the National Health Insurance Fund.
 - Description of reported outcomes
 - Description of specific population(s) (e.g. elderly patients, clinical trial participants, rare mutation profile, etc.)
 - Data modelling & extrapolation to the national population (generalisability)
 - Building of historical control arm (e.g. for comparison and/or matching)











How to collaborate?



Academic project proposals

- Open to contributing centres
- Peer review & validation by Scientific Committee
- Analysis performed by the Investigator
- Results published



Partner request for analysis

- Defined by contract
- Subject to review & amendment by appointed Steering Committee
- Analysis performed by Unicancer
- Statistical analysis report transmitted to Partner and Health Authorities
- Results published












Collaboration process

















HAUTE AUTORITÉ DE SANTÉ





Academic publication of results by Steering Committee













ESME results so far...



65 Projects

- **36** Ongoing
- 29 Completed

62 Communications

- 29 Publications
- 2 Oral presentations
- 31 Posters



ESME OC

16 Projects

- 12 Ongoing
- 4 Completed

4 Communications

- 1 Publication
- 3 Posters



ESME AMLC

29 Projects

- 14 Ongoing
- 15 Completed

16 Communications

- 1 Publication
- 13 Posters
- 2 Oral presentation









































facebook/unicancer linkedin/company/unicancer twitter.com/groupeunicancer instagram.com/reseau.unicancer







